Contact TGA: | 1800 020 653 | More contact info Translate | Subscribe

VigRX for Men capsules

Safety advisory

27 March 2014

VigRX for Men capsules pose a serious risk to your health and should not be taken.

The Therapeutic Goods Administration (TGA) has tested VigRX for Men capsules and found that they contain:

VigRX for Men pill bottle front
  • the undeclared prescription substance sildenafil - despite the package claiming to be 100% Pure Natural.
  • consumers are advised that sildenafil is a prescription-only substance (which is the active ingredient in Viagra)

The supply of VigRX for Men capsules is illegal.

VigRX for Men capsules have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA.

VigRX for Men packaging

TGA investigations have shown that a number of people in Australia have bought the product online.

Information for consumers

  • Stop taking VigRX for Men capsules and take any remaining capsules to your local pharmacy for safe disposal.
  • If you have any concerns arising from your use of this product, consult your health care practitioner.

Action the TGA is taking

The TGA is working with Australian Customs and Border Protection Services (Customs) to help stop future shipments of VigRX for Men capsules from entering Australia.

If these capsules are found at the border by Customs they will be seized and destroyed.

The TGA is advising consumers to exercise extreme caution when purchasing medicines from unknown overseas Internet sites. Products purchased over the Internet:

  • may contain undisclosed and potentially harmful ingredients
  • may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.

Report counterfeit medicines and medical devices

If you are worried about counterfeit medicines or medical devices, and want to report an issue, you can report the matter to the TGA:

Phone: 1800 020 653
Online: Report a perceived breach of the Therapeutic Goods Act or questionable practices relating to therapeutic products

Content last updated: Thursday, 27 March 2014

Web page last updated: Thursday, 27 March 2014